Roivant's autoimmune drug brepocitinib succeeds in two pivotal trials, paving way for 2027 filing
read at Endpoints ↗Positive readoutPositive
Roivant Sciences said its autoimmune drug brepocitinib met primary goals in two pivotal studies.
The trials, which evaluated the drug in separate autoimmune indications, showed statistically significant improvements compared with control.
The positive data positions brepocitinib for a regulatory filing anticipated in 2027, expanding Roivant's portfolio in autoimmune disease treatment.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Roivant's autoimmune drug succeeds in two pivotal trials, setting up 2027 filing”
read at Endpoints ↗90 words · retrieved 24m ago
comments(0)
5-min edit window · permanent after that